|
Insider Trading: ANADYS PHARMACEUTICALS INC
Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of ANADYS PHARMACEUTICALS INC in the last 24 months are illustrated in figures 1 and 2. Table 1 shows the monthly insider trading data of ANADYS PHARMACEUTICALS INC since year 2005. Table 2 shows the detailed insider transactions of ANADYS PHARMACEUTICALS INC since 2005.
The reporting company's ticker symbol is ANDS.
The reporting company's CIK number is 1128495.
The total value of stock buying since 2005 is $937,494.
The total value of stock sales is $9,157,798.
The total value of stock exercises is $611,362.
1 year stock price chart,
1 day stock price chart
opopp opopopop
Figure 1. Monthly insider transaction values at ANADYS PHARMACEUTICALS INC (ANDS) in the past 24 months.
The trade values of insider stock buys, sales, and option exercises are in logarithmic scale
as shown on the right axis labels.
The detailed monthly and daily insider transactions are listed in the 2 tables below.
08 09 10 11 12 01 2007 02 03 04 05 06 07 08 09 10 11 12 01 2008 02 03 04 05 06 07 -
Figure 2. Average prices of insider buys, sales, and option exercises at ANADYS PHARMACEUTICALS INC (ANDS) in the past 24 months. See table 2 for insider transaction details.
08 09 10 11 12 01 2007 02 03 04 05 06 07 08 09 10 11 12 01 2008 02 03 04 05 06 07 -
Table 1. Monthly summaries of insider stock purchases, sales, and option exercises
for ANADYS PHARMACEUTICALS INC (ANDS).
Trading Period
year-month |
Insider Buying
Shares Value ($) |
Insider Sales
Shares Value ($) |
Option Exercises
Shares Value ($) |
| 2008-05 | 0 | 0 | 0 | 0 | 33,898 | 99,999 |
| 2007-11 | 6,800 | 14,189 | 0 | 0 | 0 | 0 |
| 2007-09 | 107,638 | 248,280 | 0 | 0 | 0 | 0 |
| 2007-08 | 298,354 | 643,519 | 0 | 0 | 0 | 0 |
| 2007-02 | 4,170 | 14,386 | 0 | 0 | 0 | 0 |
| 2007-01 | 0 | 0 | 0 | 0 | 25,000 | 73,750 |
| 2006-12 | 2,200 | 10,120 | 0 | 0 | 0 | 0 |
| 2006-11 | 0 | 0 | 100 | 500 | 0 | 0 |
| 2006-10 | 0 | 0 | 200 | 2,042 | 0 | 0 |
| 2006-05 | 0 | 0 | 6,500 | 71,185 | 23,301 | 154,413 |
| 2006-04 | 0 | 0 | 11,500 | 170,205 | 1,500 | 4,425 |
| 2006-03 | 0 | 0 | 103,115 | 1,519,512 | 90,000 | 265,500 |
| 2006-02 | 0 | 0 | 15,870 | 193,878 | 1,500 | 4,425 |
| 2006-01 | 0 | 0 | 10,181 | 107,492 | 3,000 | 8,850 |
| 2005-12 | 0 | 0 | 5,000 | 40,740 | 0 | 0 |
| 2005-11 | 0 | 0 | 5,000 | 52,920 | 0 | 0 |
| 2005-10 | 0 | 0 | 5,000 | 54,490 | 0 | 0 |
| 2005-09 | 0 | 0 | 5,000 | 66,895 | 0 | 0 |
| 2005-08 | 0 | 0 | 5,000 | 64,185 | 0 | 0 |
| 2005-07 | 0 | 0 | 5,000 | 56,220 | 0 | 0 |
| 2005-06 | 0 | 0 | 837,768 | 6,757,534 | 0 | 0 |
| 2004-03 | 1,000 | 7,000 | 0 | 0 | 0 | 0 |
Table 2. Detailed insider stock purchases, sales, and option exercises
for ANADYS PHARMACEUTICALS INC (ANDS)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2008-05-30 | Worland Stephen T (President and CEO) | Option Exercise | 33,898 | 2.95 | 99,999 |
| 2007-11-16 | Glover James T (SVP, Operations and CFO) | Purchase | 600 | 2.00 | 1,200 |
| 2007-11-15 | Glover James T (SVP, Operations and CFO) | Purchase | 1,200 | 2.08 | 2,490 |
| 2007-11-09 | Glover James T (SVP, Operations and CFO) | Purchase | 3,401 | 2.10 | 7,142 |
| 2007-11-08 | Glover James T (SVP, Operations and CFO) | Purchase | 1,599 | 2.10 | 3,357 |
| 2007-09-14 | Papadopoulos Stelios (Director) | Purchase | 2,869 | 2.30 | 6,598 |
| 2007-09-06 | Papadopoulos Stelios (Director) | Purchase | 200 | 2.30 | 459 |
| 2007-09-05 | Papadopoulos Stelios (Director) | Purchase | 89,333 | 2.30 | 205,465 |
| 2007-09-04 | Worland Stephen T (President and CEO) | Purchase | 13,236 | 2.34 | 31,038 |
| 2007-09-04 | Williams Douglas E (Director) | Purchase | 2,000 | 2.36 | 4,720 |
| 2007-08-31 | Worland Stephen T (President and CEO) | Purchase | 12,200 | 2.12 | 25,815 |
| 2007-08-31 | Scangos George A (Director) | Purchase | 22,188 | 2.18 | 48,480 |
| 2007-08-31 | Papadopoulos Stelios (Director) | Purchase | 32,913 | 2.22 | 73,116 |
| 2007-08-30 | Worland Stephen T (President and CEO) | Purchase | 124,564 | 2.00 | 249,128 |
| 2007-08-17 | Papadopoulos Stelios (Director) | Purchase | 38,989 | 2.15 | 83,826 |
| 2007-08-16 | Xanthopoulos Kleanthis G (Director) | Purchase | 6,500 | 2.15 | 13,957 |
| 2007-08-15 | Glover James T (SVP, Operations and CFO) | Purchase | 1,000 | 2.17 | 2,169 |
| 2007-08-14 | Fritz Lawrence C (President and CEO) | Purchase | 5,691 | 2.20 | 12,501 |
| 2007-08-13 | Fritz Lawrence C (President and CEO) | Purchase | 14,309 | 2.29 | 32,767 |
| 2007-08-10 | Fritz Lawrence C (President and CEO) | Purchase | 40,000 | 2.54 | 101,760 |
| 2007-02-28 | Glover James T (SVP, Operations and CFO) | Purchase | 4,170 | 3.45 | 14,386 |
| 2007-01-12 | Worland Stephen T (President, Pharmaceuticals) | Option Exercise | 25,000 | 2.95 | 73,750 |
| 2006-12-11 | Glover James T (SVP, Operations and CFO) | Purchase | 2,200 | 4.60 | 10,120 |
| 2006-11-14 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 100 | 5.00 | 500 |
| 2006-10-09 | Yaroshevsky Glanville Mary (Vice President, Huma) | Sale | 200 | 10.21 | 2,042 |
| 2006-05-18 | Averett Devron R (Chief Scientific Officer) | Option Exercise | 14,534 | 6.88 | 99,992 |
| 2006-05-15 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 5,000 | 10.49 | 52,442 |
| 2006-05-08 | Yaroshevsky Glanville Mary (Vice President, Human Capital) | Sale | 1,500 | 12.50 | 18,743 |
| 2006-05-08 | Yaroshevsky Glanville Mary (Vice President, Human Capital) | Option Exercise | 1,500 | 2.95 | 4,425 |
| 2006-04-17 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 5,000 | 14.82 | 74,125 |
| 2006-04-10 | Reed Elizabeth E (Senior Director, Legal Affairs) | Sale | 1,500 | 13.71 | 20,560 |
| 2006-04-10 | Reed Elizabeth E (Senior Director, Legal Affairs) | Option Exercise | 1,500 | 2.95 | 4,425 |
| 2006-04-03 | Averett Devron R (Chief Scientific Officer) | Sale | 5,000 | 15.10 | 75,520 |
| 2006-03-20 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 5,000 | 15.36 | 76,800 |
| 2006-03-16 | Worland Stephen T (EVP, Pharmaceuticals) | Sale | 4,000 | 16.00 | 64,000 |
| 2006-03-07 | Yaroshevsky Glanville Mary (Vice President, Human Capital) | Sale | 1,115 | 14.72 | 16,412 |
| 2006-03-07 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 60,000 | 14.67 | 880,200 |
| 2006-03-07 | Xanthopoulos Kleanthis G (CEO and President) | Option Exercise | 60,000 | 2.95 | 177,000 |
| 2006-03-02 | Worland Stephen T (EVP, Pharmaceuticals) | Sale | 3,000 | 14.00 | 42,000 |
| 2006-02-28 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 6,141 | 12.99 | 79,752 |
| 2006-02-21 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 5,000 | 11.81 | 59,050 |
| 2006-02-17 | Averett Devron R (Chief Scientific Officer) | Sale | 3,229 | 12.02 | 38,824 |
| 2006-02-13 | Reed Elizabeth E (Senior Director, Legal Affairs) | Sale | 1,500 | 10.84 | 16,252 |
| 2006-02-13 | Reed Elizabeth E (Senior Director, Legal Affairs) | Option Exercise | 1,500 | 2.95 | 4,425 |
| 2006-01-17 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 5,000 | 11.03 | 55,134 |
| 2006-01-09 | Yaroshevsky Glanville Mary (Vice President, Huma) | Sale | 3,681 | 10.14 | 37,343 |
| 2006-01-09 | Yaroshevsky Glanville Mary (Vice President, Huma) | Option Exercise | 1,500 | 2.95 | 4,425 |
| 2006-01-09 | Reed Elizabeth E (Senior Director, Leg) | Sale | 1,500 | 10.01 | 15,015 |
| 2006-01-09 | Reed Elizabeth E (Senior Director, Leg) | Option Exercise | 1,500 | 2.95 | 4,425 |
| 2005-12-19 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 5,000 | 8.15 | 40,740 |
| 2005-11-21 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 5,000 | 10.58 | 52,920 |
| 2005-10-17 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 5,000 | 10.90 | 54,490 |
| 2005-09-19 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 5,000 | 13.38 | 66,895 |
| 2005-08-15 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 5,000 | 12.84 | 64,185 |
| 2005-07-18 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 5,000 | 11.24 | 56,220 |
| 2005-06-21 | Xanthopoulos Kleanthis G (CEO and President) | Sale | 5,000 | 8.62 | 43,105 |
| 2005-06-06 | Hbm Bioventures Ag (10% Owner) | Sale | 288,604 | 7.62 | 2,199,739 |
| 2005-06-03 | Hbm Bioventures Ag (10% Owner) | Sale | 100,000 | 8.01 | 801,099 |
| 2005-06-02 | Hbm Bioventures Ag (10% Owner) | Sale | 247,256 | 8.37 | 2,073,518 |
| 2004-03-31 | Scangos George A (Director) | Purchase | 1,000 | 7.00 | 7,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of ANADYS PHARMACEUTICALS INC (symbol ANDS,
CIK number 1128495) see
the Securities and Exchange Commission (SEC) website.
|
|
